|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
Auto Beat
Bangalore Tigers
Blogspotting
Brand New Day
Byte of the Apple
Economics Unbound
Eye on Asia
Fine On Media
Green Biz
Hot Property
Investing Insights
Management IQ
NEXT: Innovation
NussbaumOnDesign
Tech Beat
Working Parents
TECHNOLOGY
J.D. Power Ratings
Product Reviews
Tech Stats
Wildstrom: Tech Maven
AUTOS
Home Page
Auto Reviews
Classic Cars
Car Care & Safety
Hybrids
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads |  |
FEBRUARY 13, 2006
YM Biosciences' Cancer Drugs Are Working  Another tiny biotech, YM Biosciences (YMI
), trading on the Amex, may also have a winner: Tesmilifene for metastatic breast cancer. Now in Phase III trials, Tesmilifene has been shown to improve the effectiveness of commonly used chemotherapies in prolonging life. In January, YM signed a pact with Sanofi-Aventis (SNY
) to investigate the effect of combining Tesmilifene with Sanofi's Docetaxel to treat fast-growing tumors. The study will test whether using Tesmilifene together with Docetaxel enhances the survival of seriously ill patients without increasing toxicity. Initial research will be conducted in Europe and the U.S. Another YM product, for brain cancer, will go into Phase III trials soon. Mitchell Kaye of XmarkCapital Partners, the lead investor, with 10%, says Tesmilifene could generate annual sales of $1 billion. Now at 3.53 a share, YM could hit 15 in a year, Kaye figures. He also expects good results from trials of YM's AeroLef, an inhaler that provides quick pain relief to cancer victims, to be posted soon. Maher Yaghi of Desjardins Securities, who rates YM a buy, sees it making money in 2009 on projected sales of $36 million, and $43 million in 2010.
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial Get BusinessWeek directly on your desktop with our RSS feeds.  Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2006, by The McGraw-Hill Companies Inc. All rights reserved.Terms of Use | Privacy Notice |
Printer-Friendly Version